Pharma Services & Consumer Health · TECHNOLOGY
Quality Documentation Workbench.
Cleaner quality records in less time: automation drafts, checks and assembles the documents, your Quality Unit reviews and signs, and release cycle time comes down.
The problem this solves
- Batches waiting on investigation closure and record review long after manufacture
- Deviation and CAPA backlogs with recurring root causes nobody has time to trend
- Annual product reviews and tech-transfer packs assembled by hand from several systems
What we measure
- Release cycle time (end of manufacture to disposition)
- Deviation and CAPA aging, and recurrence rate
- Right-first-time on executed batch records
Every program starts by baselining these numbers in your systems. Results are reported against your baseline, not against industry averages.
The playbook
01
Investigation drafting and trending
Deviation and investigation summaries drafted from the batch record, LIMS and equipment data, linked to similar past events, with likely recurring causes flagged. The investigator writes the conclusion and the Quality Unit approves.
02
Batch record review by exception
Executed records checked against the master record and specifications, with exceptions queued for the reviewer and a full audit trail. Reviewers spend their time on what differs, under procedures your Quality Unit has approved.
03
Product review and tech-transfer packs
Annual product reviews and technology-transfer packages compiled from source systems with traceability to every data point, ready for subject-matter review and signature.
The market context, in published numbers
89%
of US prescriptions filled in 2025 were generics, which accounted for only 11.6% of total prescription drug spending
Association for Accessible Medicines, 2026 U.S. Generic & Biosimilar Medicines Savings Report (2026)
18%
of the 1,309 drug quality inspections in FDA's FY2025 report (1,248 FDA inspections plus 61 MRA partner inspections) were classified Official Action Indicated (OAI), the most serious outcome; US sites ran higher at 21.6%
12%
of nearly 10,000 FDA applications and supplements needing a facility assessment (received FY2024 to FY2025) got a Complete Response Letter because of facility withholds; FDA lists inadequate investigations and poorly documented quality-unit decisions among the citations behind them
20–50%
potential reduction in forecasting errors from applying AI-driven forecasting to supply chain management
Figures are third-party market benchmarks from the cited sources, not Ometz Partners client results. We share them so you can size the problem before we ever talk.
Capabilities
What the Technology Strategy & Deployment program covers.
Needs mapping
The workflows, data and decisions a tool must serve, written down with the owner and the metric before any vendor conversation starts.
Market scan and tool matching
Candidate tools, including the ones you already license, assessed on fit to the workflow, total cost, data residency, security posture, vendor stability and exit terms, with the alternatives shown.
Build-versus-buy decisions
Where an existing system can do the job with configuration, where a product fits, and where a scoped build is the cheaper answer, each with its cost and risk stated.
Deployment and integration
Configuration, integration through APIs and, where no API exists, tightly scoped automation into ERP, EHR and practice-management, custodial and CRM platforms, with a controlled go-live.
Governance and audit trail
Role-based access, approval steps, input and output logging, and vendor and model documentation for your risk, compliance and quality reviews.
Evaluation and monitoring
Test sets built from your real cases, accuracy and exception tracking in production, and alerts when quality, cost or usage drifts.
Quarterly stack review
Usage, cost, results and contract terms reviewed each quarter with leadership, with a short list of changes and a market update on what has moved.
Also in the Pharma Services & Consumer Health program
MARGIN
S&OP for SKU-Heavy Portfolios
A planning cycle that holds service levels on less inventory, built for long SKU tails, customer-specific packs and constrained lines.
REVENUE
Commercial Excellence: Proposals, Bids and Retail Plans
More of the right business at better prices: faster CDMO proposals, disciplined generics bids, and retailer plans for OTC brands built on real margin data.
Next step
Size this opportunity in your own numbers.
The Performance Diagnostic runs for two to four weeks at a fixed fee and ends with a baseline, three priced improvement plays and a 90-day plan. The findings are yours whether or not we continue.